Federated Hermes Inc. Purchases 14,714 Shares of argenex SE $ARGX

Federated Hermes Inc. raised its position in argenex SE (NASDAQ:ARGX) by 13.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 123,659 shares of the company’s stock after purchasing an additional 14,714 shares during the quarter. Federated Hermes Inc. owned 0.20% of argenex worth $68,163,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Goldman Sachs Group Inc. raised its holdings in argenex by 14.8% during the first quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock worth $99,886,000 after acquiring an additional 21,805 shares in the last quarter. Amundi grew its stake in argenex by 8.1% in the first quarter. Amundi now owns 6,351 shares of the company’s stock valued at $3,747,000 after purchasing an additional 478 shares in the last quarter. Voya Investment Management LLC increased its position in shares of argenex by 5.2% during the 1st quarter. Voya Investment Management LLC now owns 14,905 shares of the company’s stock worth $8,822,000 after purchasing an additional 735 shares during the last quarter. Royal Bank of Canada raised its stake in shares of argenex by 0.9% during the 1st quarter. Royal Bank of Canada now owns 38,306 shares of the company’s stock worth $22,673,000 after purchasing an additional 353 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of argenex by 40.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,611 shares of the company’s stock valued at $2,542,000 after buying an additional 1,328 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ARGX. Wolfe Research restated a “peer perform” rating on shares of argenex in a report on Monday, November 24th. Wall Street Zen raised shares of argenex from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Piper Sandler upped their target price on shares of argenex from $820.00 to $930.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Citigroup raised their target price on shares of argenex from $1,041.00 to $1,124.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Finally, Guggenheim reissued a “buy” rating and set a $1,070.00 price target on shares of argenex in a research report on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, argenex presently has an average rating of “Moderate Buy” and an average price target of $907.67.

argenex Stock Performance

Shares of ARGX stock opened at $901.17 on Monday. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62. The company has a market capitalization of $55.49 billion, a price-to-earnings ratio of 38.69, a PEG ratio of 0.91 and a beta of 0.36. The company has a 50-day simple moving average of $850.63 and a 200 day simple moving average of $707.41.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, October 30th. The company reported $4.40 earnings per share for the quarter, beating the consensus estimate of $4.37 by $0.03. The firm had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. Sell-side analysts forecast that argenex SE will post 3.13 EPS for the current year.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.